Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Monash IVF GroupMNIVF 76 EV-to-EBITDA is 9.57 as of Jul. 24, 2026, which is 3% above its 10-year median of 9.26. GuruFocus rates MNIVF with a GF Score™ of 76/100 and a GF Value™ of $0.81. The stock has 7 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Monash IVF Group ranks better than 71.79% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Monash IVF Group's enterprise value is $320.5 Mil.
Monash IVF Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $33.5 Mil. Therefore, Monash IVF Group's EV-to-EBITDA for today is 9.57.
The historical rank and industry rank for Monash IVF Group's EV-to-EBITDA or its related term are showing as below:
MNIVF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.01 Med: 9.26 Max: 62.19
Current: 9.08
During the past 12 years, the highest EV-to-EBITDA of Monash IVF Group was 62.19. The lowest was 5.01. And the median was 9.26.
MNIVF's EV-to-EBITDA is ranked better than 71.79% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.61
vs MNIVF: 9.08
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Monash IVF Group (OTCPK:MNIVF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Monash IVF Group's PE Ratio (TTM) for today is calculated as:
Monash IVF Group's share price for today is $0.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monash IVF Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.025.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Monash IVF Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Monash IVF Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monash IVF Group EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Monash IVF Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Monash IVF Group's EV-to-EBITDA falls into.
Monash IVF Group's current Enterprise Value is $320.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monash IVF Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $33.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Monash IVF Group (MNIVF) has a EV-to-EBITDA of 9.57 as of Jul. 24, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Monash IVF Group. This is near median its historical median of 9.26. Over the past decade, Monash IVF Group's EV-to-EBITDA has ranged from 5.01 to 62.19. According to the industry distribution chart, Monash IVF Group ranks #33 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 28.2%.
Is Monash IVF Group's EV-to-EBITDA too high?
Monash IVF Group's current EV-to-EBITDA of 9.57 is near median its 10-year median of 9.26. Over the past 10 years, this metric has ranged from a low of 5.01 to a high of 62.19. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.61. Monash IVF Group's value of 9.57 is 34.5% below this industry median. Based on the distribution chart, Monash IVF Group ranks #33 out of 117 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Monash IVF Group has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Monash IVF Group's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Monash IVF Group ranks #33 out of 117 companies for EV-to-EBITDA. This puts Monash IVF Group in the upper half of its industry. The industry median EV-to-EBITDA is 14.61. Monash IVF Group's value of 9.57 is 34.5% below this benchmark. Historically, Monash IVF Group's own EV-to-EBITDA has ranged from 5.01 to 62.19 over the past decade. While the company's 10-year median is 9.26 vs. the industry median of 14.61, Monash IVF Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.61, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monash IVF Group's current EV-to-EBITDA of 9.57 is 34.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Monash IVF Group. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monash IVF Group's current EV-to-EBITDA is 9.57, which is near median its own 10-year median of 9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monash IVF Group stock overvalued right now?
Monash IVF Group (MNIVF) has a current EV-to-EBITDA of 9.57. The stock's GF Value™ is $0.81, compared to a current price of $0.40 — trading 50.6% below its estimated fair value. The current EV-to-EBITDA is 9.57, which is near median its 10-year median of 9.26 and 34.5% below the Medical Diagnostics & Research industry median of 14.61. Monash IVF Group's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Monash IVF Group (MNIVF), the current EV-to-EBITDA is 9.57 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monash IVF Group (MNIVF) Overvalued in 2026?
Based on GuruFocus' analysis, Monash IVF Group stock appears to be undervalued.
The current stock price of $0.40 is trading 50.6% below its estimated GF Value™ of $0.81.
Key valuation signals for MNIVF:
EV-to-EBITDA: 9.57 (near median its 10-year median of 9.26)
GF Value™: $0.81 vs. price of $0.40 (50.6% below fair value)
Industry Position: 34.5% below the Medical Diagnostics & Research median (#33 of 117)
No single metric tells the full story. See the MNIVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monash IVF Group Ltd is a provider of fertility services, specializing in Assisted Reproductive Services (ARS) and genetic care across Australia and South East Asia. The Group operates two main segments: Australia IVF and Ultrasound, which offer ARS, ultrasound, and related women's health services, and International IVF, which provides assisted reproductive care in South East Asia. The majority of revenue is generated from the Australian segment through its brands such as Fertility Solutions, KL Fertility, Monash IVF, Repromed, and others.
76GF Score
Get the complete analysis for MNIVF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MNIVF has been successfully added to your 
